Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1

Pharmacotherapy

Volumn 29, Issue 3, 2009, Pages 295-304

  Hunt, Joshua S ^a   Romanelli, Frank ^a,b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Acquired immunodeficiency syndrome; AIDS; Coreceptor antagonism; Coreceptors; HIV; Human immunodeficiency virus; Maraviroc

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; CARBAMAZEPINE; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CLARITHROMYCIN; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEFAZODONE; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PLERIXAFOR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; TELITHROMYCIN;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; APPETITE DISORDER; ARTHROPATHY; BEDTIME DOSAGE; BILIRUBIN BLOOD LEVEL; BLOOD LEVEL; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONSTIPATION; COUGHING; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HERPES; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; LIVER TOXICITY; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; VIRUS CORE;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 62549162552     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.3.295     Document Type: Review

References (36)

1. Chan D, Kim P. HIV entry and its inhibition. Cell 1998; 93(5):681-4.
2. Baldwin CE, Sanders RW Berkhout B. Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem 2003;10(17);1633-42.
3. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART [online exclusive article]. PLoS Med 2006;3:e356. Available from http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/ journal. pmed.0030356&ct=1.
4. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CC R5 inhibitor. J Virol 2004;78:2790-807.
5. Pfizer, Inc. Selzentry (maraviroc) package insert. New York, NY; August 2007.
6. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
7. Baba M, Miyake H, Wang X, Okamoto M, Takashima K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 2007;51:707-15.
8. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small molecule inhibitor of chemokine receptor CCR5 with broad spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32.
9. Meanwell NA, Kadow JF. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 2007;8:669-81.
10. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2.
11. . Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005;33:587-95.
12. U.S. Food and Drug Administration. Pfizer Inc. Maraviroc tablets NDA 22-128. Antiretroviral drugs advisory committee (AVDAC) briefing document. April 24, 2007. Available from www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4283b1-01-Pfizer.pdf. Accessed May 10, 2008.
13. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(suppl 1):27-37.
14. Abel S, Ridgway C, Hamlin J, et al. An open, randomized, 2- way crossover study to investigate the effect of darunavir/ ritonavir on the pharmacokinetics of maraviroc in healthy subjects. Presented at the 16th international HIV drug resistance workshop, Barbados, West Indies, June 12-16, 2007.
15. Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(suppl 1):38-46.
16. Davis J, Scholler-Gyyre M, Kakuda TN, et al. An open, randomized, two period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC 125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. Presented at the 11th European AIDS conference, Madrid, Spain, October 24-27, 2007.
17. Monogram Biosciences, Inc. Trofile™ co-receptor tropism assay. Available from www.monogrambio.com/200HIVProducts.aspx. Accessed May 8, 2008.
18. Van der Ryst E, Cooper D, Konourina I, et al. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies. Presented at the 4th international AIDS society conference on HIV pathogenesis, treatment and prevention, Sydney, Australia, July 22-25, 2007.
19. Gulick RM, van der Ryst E, Lampiris H, et al. Efficacy and safety of once-daily (QD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic HIV- 1 : 2 4 -w e ek combin e d analysis of the MOTIVATE 1 and 2 studies. Presented at the 4th international AIDS society conference on HIV pathogenesis, treatment and prevention, Sydney, Australia, July 22-25, 2007.
20. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment- experienced patients infected with CCR5-tropic HIV-1: 48- week combined analysis of the MOTIVATE studies. Presented at the 1 5th conference on retroviruses and opportunistic infections, Boston, MA, February 3-6, 2008.
21. . Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind comparative trial of a novel CCR5 antagonist, maraviroc vs. efavirenz, both in combination with Combivir (zidovudine[ZDV]/lamivudine [3TC], for the treatment of antiretroviral naive patients infected with R5 HIV-1: week 48 results of the Merit study. Presented at the 4th international AIDS society conference on HIV pathogenesis, treatment and prevention, Sydney, Australia, July 22-25, 2007.
22. McHale M, Abel S, Russell D, et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). Presented at the 3rd international AIDS society conference on HIV pathogenesis and treatment, Rio de Janeiro, Brazil, July 24-27, 2005.
23. c interval in healthy subjects. Br J Clin Pharmacol 2008;65(suppl 1):68-75.
24. Hoepelman IM, Ayoub A, Heera J, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the maraviroc clinical development programme. Presented at the 11th European AIDS conference, Madrid, Spain, October 24-27, 2007.
25. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008;30:1228-50.
26. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature 1998;391:240.
27. Fernandez G, Llano A, Esgleas M, Clotet B, Este JA, Martinez MA. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. J Gen Virol 2006;87:1285-94.
28. Jensen MA, van't Wout AB. Predicting HIV-1 co receptor usage with sequence analysis. AIDS Rev 2003;5:104-12.
29. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetic and safety of AMD 3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44(6):1667-73.
30. National Institute of Health. Efficacy and safety of VICRIVIROC in HIV-infected treatment-naive subjects (study P04875AM2). Updated May 1, 2008. Available from www.clinicaltrials.gov/ct2/show/NCT00551018. Accessed May 29, 2008.
31. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4- using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20.
32. Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc in combination therapy with an optimized ART regimen for treatment experienced subjects: VICTOR-E1. Presented at the 15th conference on retroviruses and opportunistic infections, Boston, MA, February 3-6, 2008.
33. Hendrix CW, Collier AC, Lederman, et al. Safety, pharmacokinetics, and antiretroviral activity of AMD 3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37(2):1253-62.
34. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005;18:9-15.
35. Fransen S, Bridger G, Whitcomb JM. Suppression of dual tropic human immunodeficiency virus types by the CXCR4 antagonist AMD 3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrob Agents Chemother 2008;52(7):2608-15.
36. Cao YJ, Flexner CW, Dunaway S, et al. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD 070 in healthy volunteers. Antimicrob Agents Chemother 2008;52(5):1630-4.